Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment

Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB:PHRRF) has been granted a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for its “Compositions and Methods for Treating Motor Disorders” patent, intended to cover potential ketamine treatment of Parkinson’s disease and motor disorders causing involuntary or uncontrollable body actions. 

PharmaTher signed an exclusive license agreement with the University of Arizona to develop and commercialize the patent in August 2020. The results from the clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s would be made available in late-Q3 2022.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.